Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Intermediate End Points and Health Outcomes in rhGH-Treated Patients With CF (4)
This slide summarizes key findings from the systematic review about the correlation of pulmonary function and anthropometrics with mortality and HRQoL.
Other pulmonary function measures were linked to mortality and HRQoL in about half of the univariate and multivariate analyses performed and do not exhibit the predictive strength of percent predicted FEV1.
Among anthropometrics, only weight showed a consistent predictive relationship with mortality risk. However, the connection between weight with HRQoL is not clear.
Keywords: CF | HGH | HRQoL | QoL | anthropometrics | cystic fibrosis | health related quality of life | human growth hormone | mortality | multivariate | pulmonary function | quality of life | recombinant human growth hormone | regression | rhGH | univariate
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.